--- title: "Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 5.4% - Time to Buy?" description: "Recursion Pharmaceuticals (NASDAQ:RXRX) shares rose 5.4% to $5.81, despite a significant drop in trading volume. Analysts have mixed opinions, with target prices ranging from $6.00 to $11.00. The comp" type: "news" locale: "en" url: "https://longbridge.com/en/news/236280662.md" published_at: "2025-04-16T17:46:49.000Z" --- # Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 5.4% - Time to Buy? > Recursion Pharmaceuticals (NASDAQ:RXRX) shares rose 5.4% to $5.81, despite a significant drop in trading volume. Analysts have mixed opinions, with target prices ranging from $6.00 to $11.00. The company reported a quarterly EPS of -$0.53, missing estimates, and a revenue decline of 57.8% year-over-year. Institutional investors hold 89.06% of the stock, indicating strong interest. Recursion is focused on drug discovery, with several candidates in various clinical trial phases. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares traded up 5.4% on Tuesday . The stock traded as high as $5.85 and last traded at $5.81. 3,085,222 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 11,835,804 shares. The stock had previously closed at $5.51. ## Wall Street Analyst Weigh In - Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite? RXRX has been the subject of several research analyst reports. Leerink Partners reduced their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. KeyCorp reduced their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Needham & Company LLC reissued a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, April 8th. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Morgan Stanley reduced their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $8.20. **Get Our Latest Stock Analysis on RXRX** ## Recursion Pharmaceuticals Stock Up 0.7 % - Biotechs on the Brink: 2 Stocks With Huge Potential The company has a market cap of $2.23 billion, a P/E ratio of -3.63 and a beta of 1.00. The stock has a 50-day moving average of $6.78 and a 200 day moving average of $6.82. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. During the same quarter in the previous year, the firm posted ($0.42) earnings per share. Recursion Pharmaceuticals's quarterly revenue was down 57.8% compared to the same quarter last year. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year. ## Hedge Funds Weigh In On Recursion Pharmaceuticals - AI Pharma: 2 Paths to AI-Powered Drug Investment A number of institutional investors have recently modified their holdings of RXRX. Vanguard Group Inc. raised its stake in Recursion Pharmaceuticals by 40.1% during the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after acquiring an additional 9,737,196 shares in the last quarter. Softbank Group CORP. acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth approximately $99,152,000. State Street Corp increased its position in Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after purchasing an additional 4,120,685 shares in the last quarter. Novo Holdings A S acquired a new stake in Recursion Pharmaceuticals in the fourth quarter valued at approximately $68,375,000. Finally, Geode Capital Management LLC grew its stake in shares of Recursion Pharmaceuticals by 12.1% during the fourth quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company's stock worth $41,160,000 after buying an additional 655,238 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock. ## About Recursion Pharmaceuticals (Get Free Report) Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. ## Recommended Stories - Five stocks we like better than Recursion Pharmaceuticals - How to Invest in Tech Stocks and Top Tech Stocks to Consider - Beware of BigBear.ai: Insiders Are Selling—Should You? - Special Purpose Acquisition Company (SPAC) What You Need to Know - CrowdStrike Stock is a Buy as Cyberthreat Environment Expands - Stock Sentiment Analysis: How it Works - Congress! Who Traded What During the Tariff-Induced Meltdown *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Recursion Pharmaceuticals Right Now? Before you consider Recursion Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list. While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [RXRX.US - Recursion Pharmaceuticals](https://longbridge.com/en/quote/RXRX.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 美股異動速遞：Abits 大漲 163.29%，Rackspace Tech 漲 64.49%，Twin Vee PowerCats 跌 54.59% | 美股市場概況當前市場呈現出明顯的強弱分化，科技股和小盤股的表現尤為突出。Abits 的暴漲引發了市場的廣泛關注，成交量大幅放大，顯示出資金的強烈介入。與此同時，部分股票如 Twin Vee PowerCats 和 Interactive S | [Link](https://longbridge.com/en/news/276477237.md) | | 彭博新聞報道，康菲石油正在考慮出售其價值 20 億美元的二疊紀資產 | 2 月 20 日（路透社）- 據彭博新聞週五報道，康菲石油正在探索出售其部分二疊紀盆地資產，這是其更廣泛的投資組合精簡的一部分，消息人士透露。這些資產是通過與 Concho Resources 和 Shell（SHEL.L）的交易在多年中收 | [Link](https://longbridge.com/en/news/276478732.md) | | 谷歌突然發佈 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌發佈了最新的大模型 Gemini 3.1 Pro，其推理性能較去年發佈的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 評測中，Gemini 3.1 Pro 得分 77.1%，顯示出強大的推理能力。新模型支持多源數據綜合和複雜 | [Link](https://longbridge.com/en/news/276396515.md) | | 沃爾瑪四季度財報超預期但盈利指引不及預期，CEO 稱 “美國低收入家庭只能勉強維持生計” | 沃爾瑪 Q4 營收超預期，新財年盈利指引（每股 2.75-2.85 美元）遠低於市場預期的 2.96 美元，顯示通脹壓力下消費者支出不確定性猶存，拖累股價下跌 1.38%。財報印證 K 型” 分化：高收入家庭驅動增長，低收入羣體 “錢包吃緊 | [Link](https://longbridge.com/en/news/276398633.md) | | GRAIL｜8-K：2025 財年 Q4 營收 43.6 百萬美元超過預期 | | [Link](https://longbridge.com/en/news/276379877.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.